Days before it was to go into effect, the Trump administration pushed back a U.S. customs rule threatening the supply of vital prescription drugs imported by millions of Americans. Under the rule, Customs and Border Protection and the FDA will require coding on packages that makes it easier to know what’s in them. It is…
This is the 28th Employer Health Benefits Survey (EHBS) and reflects employer-sponsored health benefits in 2026. As in years past, the survey examines trends in employer coverage, including premiums, employee contributions, deductibles, offer rates, and employer practices. This year, we asked employers detailed questions about satisfaction with their health plans; coverage of GLP-1 agonists and…
Workers are paying on average $7,471 annually toward the premiums for employer-sponsored family health benefits this year, which is up 9%, or $621, from 2025, per KFF’s annual benchmark health benefits survey of large and small employers. The burden of family premiums hits particularly hard for workers at small firms with less than 200 workers.
By MIKE MAGEE MD I read with interest, Dr. Rachael Bedard’s September 25, 2026 New York Times article titled “Being a Doctor Will Never Be the Same After A.I.” In her second paragraph she writes “Amid our recent doom cycle about whether A.I. will lead to extreme societal harms, a parallel anxiety has taken hold…
At the ADAPT conference in Santa Fe, NM, panelists discuss the importance of AI sandboxes in healthcare for pilot testing, regulatory flexibility, and improving data exchange among providers
Judi Health launched Judi Rx Retire, an employer-sponsored Medicare Part D plan designed to improve pricing transparency and streamline benefits administration. The post Judi Health Launches Medicare Part D Plan for Employers appeared first on MedCity News.
New Work Group will develop peer-led guidance to help healthcare organizations prepare for AI-driven cyber threats
Regular testing of downtime procedures and understanding system dependencies are crucial for maintaining patient safety during outages, a panel of experts at the ADAPT conference says
GSK’s Hibsago brings a new mechanism of action to chronic hepatitis B, targeting the genetic instructions the virus uses to make copies of itself and viral proteins. This drug was licensed from antisense oligonucleotide specialist Ionis Pharmaceuticals. The post GSK Wins FDA Nod for Novel Hepatitis B Drug Offering a Potential Functional Cure appeared first…
As generative AI moves toward performing increasingly consequential clinical functions, the American Medical Association (AMA) is urging the U.S. Food and Drug Administration to address a foundational question: Who is responsible for ensuring that these tools remain safe once they enter clinical practice? The post AMA Calls for Risk-Based GenAI Oversight to Protect Patients and…